Monday, April 28, 2014
Xeris Pharmaceuticals Inc., of Austin, Texas, said it dosed the first subject in a phase II study of its stable liquid glucagon in an Insulet Corp.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.